How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Factorial Energy Inc. (NASDAQ: FAC) is in focus today, a day after making its Nasdaq debut following the completion of its SPAC merger with Cartesian Growth Corporation III. Factorial is a ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Recursion Pharmaceuticals’ latest earnings call struck a cautiously optimistic tone as management highlighted its first AI-enabled clinical proof-of-concept, major cost cuts, and an extended cash ...

Stellantis holds 9.5% stake in solid state battery startup Factorial, filing shows Automaker Stellantis holds a 9.5% stake in U.S. solid-state battery startup Factorial Energy and might ‌buy further ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

The history of covered call exchange-traded funds, or ETFs, in the U.S. can largely be traced back to the launch of the Invesco S&P 500 BuyWrite ETF (ticker: PBP) in December 2007. The fund was ...